Characteristics | n = 351 |
---|---|
Sex | Â |
 Male | 195 (55.6) |
 Female | 156 (44.4) |
Age, years | 55.4 ± 14.4 |
SBP, mmHg | 125.5 ± 15.9 |
DBP, mmHg | 75.9 ± 10.0 |
BMI, kg/m2 | 22.9 ± 3.1 |
Duration, years | 6.0 (2.0, 11.0) |
HbA1c, % | 7.1 ± 1.5 |
HbA1c, mmol/mol | 54 ± 16 |
C-P, ng/mL | 1.4 (0.6,2.0) |
Comorbidity | Â |
 Hypertension | 45 (12.8) |
 Hyperlipidemia | 59 (16.8) |
 Fatty liver | 19 (5.4) |
 CCVD | 37 (10.5) |
Medication | Â |
 Metformin | 97 (27.6) |
 DPP-4i | 57 (16.2) |
 SGLT-2i | 15 (4.3) |
 α-GI | 65 (18.5) |
 GLP-1ra | 6 (1.7) |
 TZD | 9 (2.6) |
 SU | 78 (22.2) |
 Insulin therapy | 137 (39.0) |
 Long-acting insulin | 78 (22.2) |
 Premixed insulin | 36 (10.3) |
 Short-acting insulin | 58 (16.5) |
Complication | Â |
 DR | 54 (15.4) |
 DPN | 45 (12.8) |
 DPVD | 17 (4.8) |
 DN | 17 (4.8) |
 DF | 2 (0.6) |
CGM data | Â |
 AH (%) | 137 (39.0) |
  Total TIR, % | 84.9 (66.7,96.0) |
  Nighttime TIR, % | 96.8 (76.0, 100.0) |
  Daytime TIR, % | 81.9 (61.6,95.6) |
  Total TBR, % | 2.1 (0.8,5.8) |
  Nighttime TBR, % | 1.8 (0.0, 10.2) |
  Daytime TBR, % | 1.1 (0.2,3.7) |
  Total TAR, % | 12.7 (2.2,32.1) |
  Nighttime TAR, % | 0.0 (0.0, 17.1) |
  Daytime TAR, % | 16.2 (2.9,37.6) |
 Level 1 AH (%) | 84 (23.9) |
  Total TIR, % | 89.4 (77.6,97.2) |
  Nighttime TIR, % | 96.3 (80.4, 100.0) |
  Daytime TIR, % | 88.9 (72.6,97.0) |
  Total TBR, % | 1.0 (0.6,2.6) |
  Nighttime TBR, % | 0.1 (0.0,6.3) |
  Daytime TBR, % | 0.8 (0.2, 1.5) |
  Total TAR, % | 6.2 (1.0,23.2) |
  Nighttime TAR, % | 0.0 (0.0,2.2) |
  Daytime TAR, % | 8.2 (1.3,26.8) |
 Level 2 AH (%) | 53 (15.1) |
  Total TIR, % | 74.8 (67.0,85.7) |
  Nighttime TIR, % | 81.0 (65.5,95.5) |
  Daytime TIR, % | 74.3 (63.3–85.3) |
  Total TBR, % | 4.8 (2.5,8.6) |
  Nighttime TBR, % | 4.6 (1.3, 18.2) |
  Daytime TBR, % | 3.4 (1.0,7.2) |
  Total TAR, % | 18.3 (3.9,28.5) |
  Nighttime TAR, % | 0.7 (0.0, 19.0) |
  Daytime TAR, % | 20.6 (5.3,33.8) |
 DAH (%) | 112 (31.9) |
  Hypoglycemic events | 3.0 (1.0, 10.0) |
  Hypoglycemic duration, min | 27.0 (11.5,94.5) |
NAH (%) | 85 (24.2) |
 Hypoglycemic events | 6.0 (3.0, 12.0) |
 Hypoglycemic duration, min | 51.0 (23.0, 103.0) |
DAH*(%) | 52 (14.8) |
 Hypoglycemic events | 1.0 (1.0, 3.0) |
 Hypoglycemic duration, min | 12.0 (4.5, 25.0) |
NAH*(%) | 25 (7.1) |
 Hypoglycemic events | 1.0 (0.0, 4.0) |
 Hypoglycemic duration, min | 6.0 (0.0, 37.0) |
 Both DAH and NAH (%) | 60 (17.1) |
 Hypoglycemic events | 8.0 (3.0, 14.5) |
 Hypoglycemic duration, min | 68.0 (27.0,135.0) |
  MAGE, mmol/L | 4.2 ± 2.2 |
  SD, mmol/L | 1.9 ± 0.9 |
  MBG, mmol/L | 8.2 ± 2.1 |